1Breitfeld P P, Meyer W H windows of opportunity[J]. Rhabdomyosarcoma : new Oncologist, 2005, 10:518-527.
2Newton WA Jr, Gehan E A, Webber B I., et al. Clas- sification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification an Intergroup Rhabdomyosarcoma Study[J]. Cancer, 1995, 76:1073-1085.
3Ferret F A, Isakoff M, Koyle M A. Bladder/prosiate rhabdomyosarcoma: past, present and future [J]. J Urol, 2006, 176:1283-1291.
4Michelagnoli M P, Burchill S A, Cullinane C, el ai. Myogenin-a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1 [J]. Med PediatrOncol, 2003, 40:1-8.
5Sorensen P H, Lynch J C, Qualman S J, etal. PAX3- FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's ontology group[J]. J Clin Oncol, 2002, 20:2672-2679.
6Sharp R, Recio J A, Jhappan C, et al. Synergism be- tween INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis[J]. Nat Med, 2002, 8:1276- 1280.
7Ciarapica R, Russo G, Verginelli F, et al. Deregulatedexpression of miR-26a and Ezh2 in rhabdomyosarcoma [J]. CellCycle, 2009, 8:172-175.
8Wang H, Garzon R, Sun H, et al. NF-kappaB-YY1- miR-29 regulatory circuitry in skeletal myogenesis and rhabdornyosarcoma[J]. Cancer Cell, 2008, 14: 369 - 381.
9Wu H Y, Snyder H M 3rd, Womer R B. Genitourinar- y rhabdomyosarcoma: which treatment, how much, and when[J]? J Pediatr Urol, 2009, 5:501-506.
10Leaphart C, Rodeberg D. Pediatric surgical oncology: Manage- ment of rhabdomyosarcomal. Surg Oncol, 2007, 16 (3) : 173- 185.
